QBiotics Board and Executive update

BRISBANE, 18 December 2025

QBiotics Group Limited (QBiotics) advises it has made a number of Board and Executive leadership changes, effective immediately, that will support the Company’s next phase of growth and stability. This includes appointing an interim Chair, an interim Chief Executive Officer, reinstating founder Dr Paul Reddell as Chief Scientific Officer and appointing Dr Victoria Gordon as Chief Strategy Officer. Mr David Phillips has stepped down as a Non-Executive Director due to other professional commitments.

Key appointments and changes

• Mr Simon Pollard appointed as Interim Non-Executive Chairman
• Ms Ebru Davidson appointed as Interim Chief Executive Officer and Managing Director
• Dr Paul Reddell reinstated as Chief Scientific Officer
• Dr Victoria Gordon appointed as Chief Strategy Officer
• Mr David Phillips has stepped down as a Non-Executive Director

Interim Non-Executive Chairman, Mr Simon Pollard, said:

“These appointments bring together a leadership team with deep institutional knowledge, strong governance capability and a clear focus on execution. I look forward to leading the Board and believe with this composition, we will establish stability and continuity, while positioning QBiotics to progress its clinical programs, strengthen commercial pathways and deliver long-term value for shareholders.”

Co-Founder and Chief Strategy Officer, Dr Victoria Gordon, said:

“Over the past 25 years, QBiotics has achieved resilience and sustained progress. I am confident that the appointments that have been made deliver the experience and expertise to advance our pipeline and continue to strengthen our business.”

“We are delighted that Ebru Davidson has agreed to step into the interim CEO role. Having been closely involved with the business for ten years, both inhouse and as a valued external advisor and committed shareholder, Ebru brings deep insight into our operations, strategy, investor relations and culture to the position. We look forward to the continuity and strategic clarity she will bring to the interim CEO role as we progress our next phase of growth.”

“Simon steps into the role of Interim Non-executive Chair of the Board as both an engaged shareholder, and with a deep understanding of our operations. He brings extensive expertise in corporate finance, commercial transactions, and negotiation, alongside strong legal and governance experience across multiple sectors. This makes Simon well positioned to support the Company’s strategic initiatives and drive value through sound commercial and transactional guidance.”

“On behalf of the board, I would also like to thank David for his contributions to the Company and the experience he has brought across a range of areas, including finance and the biotech industry. We wish him all the best for the future.”

Incoming Interim Chief Executive Officer and Managing Director, Ms Ebru Davidson, said:

“I’m immensely proud to be stepping into the role of Interim CEO and Managing Director at this important stage for QBiotics. Having worked closely with the team for many years, I am absolutely committed to the power of our science and our potential to make a genuine difference for patients. This is an opportunity to sharpen our focus, accelerate our clinical programs, and help realise the company’s full potential.”

The Board also confirms that it will continue to review its composition to ensure alignment with the Company’s strategic objectives and will keep shareholders informed of any further developments.

Further detail on appointments

Mr Simon Pollard – Interim Non-Executive Chairman

Mr Pollard is an experienced director and senior executive with deep expertise in strategy, governance, capital markets and global commercialisation. He understands the QBiotics business well, having initially invested, and then serving as Chief Commercial Officer between 2016 and 2019.

Mr Pollard has held senior leadership roles at global organisations, including IBM and HSBC, leading large-scale operations and driving sustained revenue growth across Asia-Pacific, Europe and the US.

He brings significant Board, Chair and advisory experience across public and private companies, with a strong track record in capital raising, partnerships, M&A and value creation, including the successful commercialisation of healthcare, life sciences and technology assets.

Ms Ebru Davidson – Interim CEO and Managing Director

Ms Davidson brings extensive commercial, legal and governance experience to the role. She has advised on significant capital markets transactions, M&A and complex corporate matters, with deep expertise in growth-stage companies and regulatory frameworks. She served as an external advisor to QBiotics from 2015 to 2021 before joining the Company as General Counsel in 2021, where she has played a key role in Board matters, investor engagement, strategy and corporate governance.

Ms Davidson was formerly a partner in Thomson Geer’s Equity Capital Markets team and holds a Bachelor of Science and a Juris Doctor (Honours). She currently serves as a Non-Executive Director of Kazia Therapeutics Limited (NASDAQ: KZIA) and the Centre for Eye Research Australia.

Dr Paul Reddell – Chief Scientific Officer (CSO)

The Board of QBiotics, following legal advice and careful consideration of all relevant circumstances, has resolved to set aside the purported termination of Dr Reddell’s employment and reinstate Dr Reddell to his former role of CSO. The Board sincerely apologises to Dr Reddell for the negative impact the purported termination caused him and is pleased that he has accepted reinstatement as CSO.

Dr Reddell is a Co-Founder of QBiotics and has been integral to the Company’s success since its inception, providing more than 25 years of scientific and strategic leadership at both Board and Executive levels.

Dr Reddell remains an essential member of the QBiotics leadership team, and his ongoing involvement ensures continuity of scientific leadership as the Company progresses its next phase of growth and development.

Dr Victoria Gordon – Chief Strategy Officer

A co-founder of the QBiotics Group, Dr Gordon brings 25 years of experience with the organisation, including nearly 24 years of distinguished service as Chief Executive Officer. Her long-standing leadership role, combined with deep expertise across both the corporate and scientific dimensions of the business, has provided her with comprehensive, enterprise-wide knowledge of the Company’s operations, research and development, and strategic priorities. Dr Gordon’s strategic leadership has been consistently demonstrated throughout her tenure, making her a natural and highly qualified appointment to the role of Chief Strategy Officer.

—ends—
 

FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO & MANAGING DIRECTOR
communications@qbiotics.com

or

MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774

 
NOTES FOR EDITORS

ABOUT QBIOTICS

QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialisation to harness the power of nature to treat diseases of high unmet need. 

Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program.

QBiotics’ lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumours. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024.

A veterinary formulation of tigilanol tiglate (STELFONTA^®) is approved for the treatment of canine mast cell tumours (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA^®.

Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment.